January 8, 2021 -- Integral Molecular and Optimeos Life Sciences have partnered to develop novel antibody therapeutics using long-acting, sustained delivery formulations.
In the partnership, Integral will use its MPS antibody discovery platform while Optimeos will use its inverse flash nanoprecipitation (iFNP) technology to reduce the frequency of injections for patients.
The MPS platform is capable of isolating antibodies against difficult proteins, overcoming traditional challenges such as target concentration and structurally complex antigens.
The iFNP technology was originally developed by Robert Prud'homme, PhD, at Princeton University, and it allows for the robust and scalable incorporation of therapeutic antibodies and other biologics into customizable nanoparticles. Prud'homme is also the co-founder and chief scientific officer of Optimeos.
Financial details of the partnership were not disclosed.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
